Gingerenone A prodrugs as sensotherapeutics and methods of use

US12325688B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Ruin Moaddel · Bel Air, US
• Luigi Ferrucci · Baltimore, US
• Kotb Abdelmohsen · Nottingham, US
• Myriam Gorospe · Elliot, US
• Martina Rossi · Baltimore, US
• Christopher Ramsden · Bethesda, US
• Gregory S. Keyes · Dexter, US

Key dates

• Filing date: Jan 17, 2023
• Grant date: Jun 10, 2025
• Expiry date: Jan 17, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C229/38
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Gingerenone A prodrug compounds have a structure according to Formula I, or a pharmaceutically acceptable salt thereof wherein one of R1 and R2 is H or —C(O)—R and the other of R1 and R2 is —C(O)—R. Each R independently is RA or, where RA is C18-C22 alkenyl, and RB is an amino acid side chain. The compounds are useful for inhibiting or eliminating senescence. The compounds may be administered to a subject having a senescence-associated disease or disorder, neuroinflammation, pain, and/or an amino acid deficiency.